Mittal A, Hutchinson HJ, Lucke-Wold BP. Cytomegalovirus reactivation and the prevalence in autologous hematopoietic stem cell transplantation. World J Virol 2026; 15(1): 117651 [DOI: 10.5501/wjv.v15.i1.117651]
Corresponding Author of This Article
Brandon P Lucke-Wold, MD, PhD, Academic Fellow, Lillian S. Wells Department of Neurosurgery, University of Florida, 1505 SW Archer Road, Gainesville, FL 32608, United States. brandon.lucke-wold@neurosurgery.ufl.edu
Research Domain of This Article
Transplantation
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Mar 25, 2026 (publication date) through Mar 13, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Virology
ISSN
2220-3249
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Mittal A, Hutchinson HJ, Lucke-Wold BP. Cytomegalovirus reactivation and the prevalence in autologous hematopoietic stem cell transplantation. World J Virol 2026; 15(1): 117651 [DOI: 10.5501/wjv.v15.i1.117651]
World J Virol. Mar 25, 2026; 15(1): 117651 Published online Mar 25, 2026. doi: 10.5501/wjv.v15.i1.117651
Cytomegalovirus reactivation and the prevalence in autologous hematopoietic stem cell transplantation
Agastya Mittal, Hunter J Hutchinson, Brandon P Lucke-Wold
Agastya Mittal, Hunter J Hutchinson, College of Medicine, University of Florida, Gainesville, FL 32601, United States
Brandon P Lucke-Wold, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL 32608, United States
Author contributions: Mittal A was responsible for data collection and writing the original draft; Hutchinson HJ was responsible for writing review and editing; Lucke-Wold BP was responsible for supervision and writing review; all authors read and approved the final manuscript to be published.
Conflict-of-interest statement: The authors have no relevant financial or non-financial interests to disclose.
Corresponding author: Brandon P Lucke-Wold, MD, PhD, Academic Fellow, Lillian S. Wells Department of Neurosurgery, University of Florida, 1505 SW Archer Road, Gainesville, FL 32608, United States. brandon.lucke-wold@neurosurgery.ufl.edu
Received: December 12, 2025 Revised: January 9, 2026 Accepted: January 27, 2026 Published online: March 25, 2026 Processing time: 91 Days and 15.1 Hours
Abstract
In this article, we comment on the article by Ben Moussa et al published discussing cytomegalovirus (CMV) reactivation in patients who have undergone autologous hematopoietic stem cell transplantation (AHSCT). CMV reactivation is a heavily discussed complication when discussing allogenic hematopoietic stem cell transplantation, but much more limited discussion in AHSCT. These issues are further complicated by a lack of concrete guidelines for CMV reactivation after AHSCT, especially viral load thresholds which have been shown to be the strongest correlation to determine the occurrence and severity of CMV reactivation. Although antiviral prophylaxis and testing does exist, it is limited and rarely extends beyond d100, limiting response effectiveness to delayed acting CMV reactivation or other delayed autoimmune disease.
Core Tip: Reactivation of cytomegalovirus (CMV) is a crucial consideration in autologous hematopoietic stem cell transplantation (AHSCT), yet it is often overlooked. Given the increasing prevalence of CMV reactivation in AHSCT, centralized guidelines for its screening and assessment would improve patient outcomes. This is especially pertinent given the high mortality rate of CMV reactivation in AHSCT.
